RESPONSE

Claims 1-92 are pending in the subject application. The election, described below, identifies claims 10-47 and 82-92 for further prosecution.

In response to the restriction requirement among Groups 1-46, Applicant elects Group 21 (SEQ ID NO: 4) as the invention peptide for further prosecution. Applicant further elects a formulation comprising beta-interferon (β-interferon). Accordingly, Applicant elects linking claims 1-47 and 82-92 insofar as these claims recite the invention to be examined.

Applicant makes these elections with traverse and without waiver as to right to rejoinder or under 103(b).

Examination of the elected claims and subject matter is respectfully requested.

Respectfully Submitted,

Peter J. Knudsen, Esq.

Attorney/Agent for Applicants

Reg. No. 40,682

January 30, 2006 Date

Peter J. Knudsen 3450 Monte Villa Parkway Bothell, Washington 98021-8909

Tel. 425-908-3643

Facsimile: 425-908-3653 pknudsen@nastech.com

I hereby certify that this correspondence of 22 pages is being deposited with the United States Postal Service with sufficient postage as First Class Mail addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below. Signature Typed or printed name Patricia J. Utter Date January 30, 2006